

MIMS[®] INDIA

MONTHLY INDEX OF MEDICAL SPECIALITIES

Volume 18 Number 12

December, 1998

Editor: Dr. C.M. Gulhati

MIMS—an independent professionally edited index of ethical preparations available for prescription in India. It is for use only by registered medical practitioners and pharmacists. As MIMS is amended each month, out of date copies should not in any event be referred to. Although pharmaceutical manufacturers send details on their products to MIMS, all the product entries and new drug reviews are independently written and edited by MIMS' own staff.

Monographs are written on the basis of authentic information from diverse sources such as text books, medical journals, clinical trials, MIMS editions from other countries and information from drug regulatory authorities around the world.

The necessity to keep information concise and in a form considered to be most useful to prescribers means that certain details such as additional ingredients (e.g. gluten, colouring agents) cannot be included; when full product information is required it may be obtained from the Editor of MIMS or the appropriate manufacturer. While every effort is made to ensure that the contents are accurate at the time of going to press, the publishers and printers can accept no responsibility for errors or omissions caused either in the preparation or the printing of the journal.

MIMS INDIA
90, Nehru Place,
New Delhi-110019

MIMS[®]
INDIA

December 31, 1998
(Update:
November 30, 1998)

REVIEW:
Tea: New Tonic for Heart

Founded: 1959

ISSN: 0970-1036

CONTENTS

- 2 From the Editor's Desk
- 3 Readers' Forum
- 5 Pharmacological Index
- 6 Review: Tea - A Newly Discovered Cardioprotectant
- 11 New Entries
- 13 General Index of Products
- 23 Eradication regimens for *H. Pylori* Chart
- 52 Management of Hypertension Chart
- 140 Summary of Antibacterial Therapy Chart
- 159 Antibiotic Prophylaxis for Surgery Chart
- 162 Antibacterial Classes & Formulations Chart
- 211 Management of Asthma Chart
- 257 Management of Lipid Levels Chart
- 264 Generic-Brand Index
- 286 Therapeutic Index
- 288 Deleted Products
- 290 Directory of Manufacturers
- 293 Alphabetical Index

Founder
Late Alfred E. Morgan

Editor
Dr. Chandra M. Gulhati

Editorial Production Controller
Pooja Sharma

Subscriptions
Neera Sharma

Sales
Anu Sharma

E.D.P.
Shilpi Verma

Single Copy
Rs. 45

Annual Subscription
Rs. 270

6 JAN 1999

or

orrow!

S
relapse

ns
quinolones

*MIMS INDIA is the registered trade mark.
Copyright A.E. Morgan Publications (India) Private Limited.
All rights reserved. Worldwide copyrights held by publishers in respect of style of presentation, Pharmacological and Therapeutic Indices. No part of the publication may be reproduced in any form whatsoever without the written permission of the publisher.
Published, edited and printed by Dr. C.M. Gulhati from 90, Nehru Place, New Delhi 110019. Printed at Indraprastha Press, Bahadur Shah Zafar Marg, New Delhi 110002.*

A. E. Morgan Publications (India) Private Limited
503 Mansarovar, 90 Nehru Place, New Delhi 110019
Tel: 6414693, 6433115, 6234875, 6463720
Fax: 011 6424016. E-mail: mims@ndb.vsnl.net.in

39.

DDO / 71/na

doses after food adjusted to maintain urinary cystone below 200mg/litre. See literature.

C/I: Lupus erythematosus.

Agranulocytosis, thrombocytopenia. Pregnancy, lactation.

S/P: Penicillin sensitivity. Monitor blood, liver & renal functions frequently during treatment.

Renal insufficiency.

D/INT: Gold salts, antimalarial or cytotoxic drugs, phenylbutazone, antacids, zinc or iron salts.

ADR: Nausea, anorexia, fever, rash, loss of taste, proteinuria, haematuria, blood dyscrasias, nephrotic syndrome, SLE, myasthenia gravis.

CALSYNAR RHONE-POULENC

Synthetic salmon calcitonin 100i.u., per ml; amps.

Paget's disease. Postmenopausal osteoporosis. Osteolytic hypercalcaemia of malignancy. Metastatic bone pain.

5 amps., Rs. 850

Paget's disease: 50i.u. 3 times weekly to 100i.u. daily in single or divided doses by s.c. or i.m. injection.

Postmenopausal osteoporosis: 100i.u. daily by s.c. or i.m. inj. Patients should also receive 600mg elemental calcium & 400 units vit. D daily.

Hypercalcaemia: 400i.u. 6-8 hourly by s.c. or i.m. inj.; max. 8i.u./kg every 6 hours. *Metastatic bone pain:* 200i.u. 6 hourly or 400i.u. 12 hourly by s.c. or i.m. inj. for two days.

Children: Not recommended for periods of more than a few weeks.

C/I: Hypersensitivity.

S/P: History of allergy-perform scratch test. *Pregnancy, lactation. Cardiac, renal failure.*

D/INT: Cardiac glycosides.

ADR: Nausea, vomiting, flushing, tingling hands, unpleasant taste. *Allergic reactions.*

DESFERAL Novartis

Desferrioxamine 500mg; vials.

Acute iron poisoning, haemochromatosis. Aluminium overload in dialysis patients.

Price, N/A

Iron overload: 20-40mg/kg subcutaneous infusion over 8-12 hours administered 3-7 nights each week. May also be given by infusion line when transfusing blood up to 2g per unit of blood.

See literature.

C/I: Absence of excess iron stores.

S/P: Impaired renal function.

Pregnancy, lactation. Perform eye and hearing tests on long-term therapy. May produce seizures in patients with aluminium-related encephalopathy; pretreat with clonazepam.

D/INT: Prochlorperazine, methyl dopa, erythropoietin. *Phenothiazines.*

ADR: Shock with rapid inj.

Rarely allergic reactions, cardiovascular, neurological & g-i disturbances. Red colouration of urine. Retinal & lens changes. Leg cramps. Hepatic & renal dysfunction. Blood dyscrasias.

DRONATE-OS BDH

Etidronate disodium 200mg; tabs.

Neoplastic hypercalcaemia.

Paget's disease of bone.

10, Rs. 217.39

Neoplastic hypercalcaemia: 20mg/kg as a single daily dose for 30 days. Maximum recommended treatment period: 90 days.

Paget's disease: 5mg/kg as a single daily dose for up to 6 months; doses above 10mg/kg for up to 3 months may be used with caution but doses above 20mg/kg daily are not recommended.

Children: safety & efficacy not established.

C/I: Moderate to severe renal impairment, pregnancy, lactation.

S/P: Reduce dose in mild renal impairment. Adequate nutritional intake, notably calcium & vit. D. *Enterocolitis. High-calcium food, milk, milk products, vitamins with mineral supplements or antacids should not be taken within 2 hours of administration.*

D/INT: Antacids, aminoglycosides, iron, calcium salts.

ADR: Nausea, diarrhoea, asymptomatic hypocalcaemia, increased bone pain in Paget's disease, increased risk of fractures with high doses in Paget's disease (discontinue if fracture occurs), rarely skin reactions, angio-oedema, abdominal pain, constipation, transient taste loss.

D/INT: Antacids, aminoglycosides, iron, calcium salts.

ADR: Nausea, diarrhoea, asymptomatic hypocalcaemia, increased bone pain in Paget's disease, increased risk of fractures with high doses in Paget's disease (discontinue if fracture occurs), rarely skin reactions, angio-oedema, abdominal pain, constipation, transient taste loss.

ADR: Nausea, diarrhoea, asymptomatic hypocalcaemia, increased bone pain in Paget's disease, increased risk of fractures with high doses in Paget's disease (discontinue if fracture occurs), rarely skin reactions, angio-oedema, abdominal pain, constipation, transient taste loss.

ADR: Nausea, diarrhoea, asymptomatic hypocalcaemia, increased bone pain in Paget's disease, increased risk of fractures with high doses in Paget's disease (discontinue if fracture occurs), rarely skin reactions, angio-oedema, abdominal pain, constipation, transient taste loss.

ADR: Nausea, diarrhoea, asymptomatic hypocalcaemia, increased bone pain in Paget's disease, increased risk of fractures with high doses in Paget's disease (discontinue if fracture occurs), rarely skin reactions, angio-oedema, abdominal pain, constipation, transient taste loss.

ADR: Nausea, diarrhoea, asymptomatic hypocalcaemia, increased bone pain in Paget's disease, increased risk of fractures with high doses in Paget's disease (discontinue if fracture occurs), rarely skin reactions, angio-oedema, abdominal pain, constipation, transient taste loss.

ADR: Nausea, diarrhoea, asymptomatic hypocalcaemia, increased bone pain in Paget's disease, increased risk of fractures with high doses in Paget's disease (discontinue if fracture occurs), rarely skin reactions, angio-oedema, abdominal pain, constipation, transient taste loss.

ADR: Nausea, diarrhoea, asymptomatic hypocalcaemia, increased bone pain in Paget's disease, increased risk of fractures with high doses in Paget's disease (discontinue if fracture occurs), rarely skin reactions, angio-oedema, abdominal pain, constipation, transient taste loss.

ADR: Nausea, diarrhoea, asymptomatic hypocalcaemia, increased bone pain in Paget's disease, increased risk of fractures with high doses in Paget's disease (discontinue if fracture occurs), rarely skin reactions, angio-oedema, abdominal pain, constipation, transient taste loss.

ADR: Nausea, diarrhoea, asymptomatic hypocalcaemia, increased bone pain in Paget's disease, increased risk of fractures with high doses in Paget's disease (discontinue if fracture occurs), rarely skin reactions, angio-oedema, abdominal pain, constipation, transient taste loss.

ADR: Nausea, diarrhoea, asymptomatic hypocalcaemia, increased bone pain in Paget's disease, increased risk of fractures with high doses in Paget's disease (discontinue if fracture occurs), rarely skin reactions, angio-oedema, abdominal pain, constipation, transient taste loss.

ADR: Nausea, diarrhoea, asymptomatic hypocalcaemia, increased bone pain in Paget's disease, increased risk of fractures with high doses in Paget's disease (discontinue if fracture occurs), rarely skin reactions, angio-oedema, abdominal pain, constipation, transient taste loss.

ADR: Nausea, diarrhoea, asymptomatic hypocalcaemia, increased bone pain in Paget's disease, increased risk of fractures with high doses in Paget's disease (discontinue if fracture occurs), rarely skin reactions, angio-oedema, abdominal pain, constipation, transient taste loss.

ADR: Nausea, diarrhoea, asymptomatic hypocalcaemia, increased bone pain in Paget's disease, increased risk of fractures with high doses in Paget's disease (discontinue if fracture occurs), rarely skin reactions, angio-oedema, abdominal pain, constipation, transient taste loss.

ADR: Nausea, diarrhoea, asymptomatic hypocalcaemia, increased bone pain in Paget's disease, increased risk of fractures with high doses in Paget's disease (discontinue if fracture occurs), rarely skin reactions, angio-oedema, abdominal pain, constipation, transient taste loss.

ADR: Nausea, diarrhoea, asymptomatic hypocalcaemia, increased bone pain in Paget's disease, increased risk of fractures with high doses in Paget's disease (discontinue if fracture occurs), rarely skin reactions, angio-oedema, abdominal pain, constipation, transient taste loss.

ADR: Nausea, diarrhoea, asymptomatic hypocalcaemia, increased bone pain in Paget's disease, increased risk of fractures with high doses in Paget's disease (discontinue if fracture occurs), rarely skin reactions, angio-oedema, abdominal pain, constipation, transient taste loss.

ADR: Nausea, diarrhoea, asymptomatic hypocalcaemia, increased bone pain in Paget's disease, increased risk of fractures with high doses in Paget's disease (discontinue if fracture occurs), rarely skin reactions, angio-oedema, abdominal pain, constipation, transient taste loss.

ADR: Nausea, diarrhoea, asymptomatic hypocalcaemia, increased bone pain in Paget's disease, increased risk of fractures with high doses in Paget's disease (discontinue if fracture occurs), rarely skin reactions, angio-oedema, abdominal pain, constipation, transient taste loss.

ADR: Nausea, diarrhoea, asymptomatic hypocalcaemia, increased bone pain in Paget's disease, increased risk of fractures with high doses in Paget's disease (discontinue if fracture occurs), rarely skin reactions, angio-oedema, abdominal pain, constipation, transient taste loss.

ADR: Nausea, diarrhoea, asymptomatic hypocalcaemia, increased bone pain in Paget's disease, increased risk of fractures with high doses in Paget's disease (discontinue if fracture occurs), rarely skin reactions, angio-oedema, abdominal pain, constipation, transient taste loss.

ADR: Nausea, diarrhoea, asymptomatic hypocalcaemia, increased bone pain in Paget's disease, increased risk of fractures with high doses in Paget's disease (discontinue if fracture occurs), rarely skin reactions, angio-oedema, abdominal pain, constipation, transient taste loss.

ADR: Nausea, diarrhoea, asymptomatic hypocalcaemia, increased bone pain in Paget's disease, increased risk of fractures with high doses in Paget's disease (discontinue if fracture occurs), rarely skin reactions, angio-oedema, abdominal pain, constipation, transient taste loss.

ADR: Nausea, diarrhoea, asymptomatic hypocalcaemia, increased bone pain in Paget's disease, increased risk of fractures with high doses in Paget's disease (discontinue if fracture occurs), rarely skin reactions, angio-oedema, abdominal pain, constipation, transient taste loss.

divided doses. Dosage adjustment at 4 weeks or more intervals. **Not recommended for children below 18 years.**

C/I: Active liver disease.

Pregnancy; adequate contraception must be used. Lactation.

S/P: History of liver disease; test eye & perform liver function tests during treatment. Withdraw if creatine phosphokinase levels markedly raised.

D/INT: Take 1 hour before or 4 hour after cholestyramine or colestipol. *Immunosuppressive drugs, nicotinic acid, erythromycin, rifampicin, gemfibrozil & other fibrates.*

ADR: Rash, muscle toxicity, headache, non-cardiac chest pain, nausea, vomiting, diarrhoea, fatigue.

D/INT: Take 1 hour before or 4 hour after cholestyramine or colestipol. *Immunosuppressive drugs, nicotinic acid, erythromycin, rifampicin, gemfibrozil & other fibrates.*

ADR: Rash, muscle toxicity, headache, non-cardiac chest pain, nausea, vomiting, diarrhoea, fatigue.

D/INT: Take 1 hour before or 4 hour after cholestyramine or colestipol. *Immunosuppressive drugs, nicotinic acid, erythromycin, rifampicin, gemfibrozil & other fibrates.*

ADR: Rash, muscle toxicity, headache, non-cardiac chest pain, nausea, vomiting, diarrhoea, fatigue.

D/INT: Take 1 hour before or 4 hour after cholestyramine or colestipol. *Immunosuppressive drugs, nicotinic acid, erythromycin, rifampicin, gemfibrozil & other fibrates.*

ADR: Rash, muscle toxicity, headache, non-cardiac chest pain, nausea, vomiting, diarrhoea, fatigue.

D/INT: Take 1 hour before or 4 hour after cholestyramine or colestipol. *Immunosuppressive drugs, nicotinic acid, erythromycin, rifampicin, gemfibrozil & other fibrates.*

ADR: Rash, muscle toxicity, headache, non-cardiac chest pain, nausea, vomiting, diarrhoea, fatigue.

D/INT: Take 1 hour before or 4 hour after cholestyramine or colestipol. *Immunosuppressive drugs, nicotinic acid, erythromycin, rifampicin, gemfibrozil & other fibrates.*

ADR: Rash, muscle toxicity, headache, non-cardiac chest pain, nausea, vomiting, diarrhoea, fatigue.

D/INT: Take 1 hour before or 4 hour after cholestyramine or colestipol. *Immunosuppressive drugs, nicotinic acid, erythromycin, rifampicin, gemfibrozil & other fibrates.*

ADR: Rash, muscle toxicity, headache, non-cardiac chest pain, nausea, vomiting, diarrhoea, fatigue.

D/INT: Take 1 hour before or 4 hour after cholestyramine or colestipol. *Immunosuppressive drugs, nicotinic acid, erythromycin, rifampicin, gemfibrozil & other fibrates.*

ADR: Rash, muscle toxicity, headache, non-cardiac chest pain, nausea, vomiting, diarrhoea, fatigue.

D/INT: Take 1 hour before or 4 hour after cholestyramine or colestipol. *Immunosuppressive drugs, nicotinic acid, erythromycin, rifampicin, gemfibrozil & other fibrates.*

ADR: Rash, muscle toxicity, headache, non-cardiac chest pain, nausea, vomiting, diarrhoea, fatigue.

D/INT: Take 1 hour before or 4 hour after cholestyramine or colestipol. *Immunosuppressive drugs, nicotinic acid, erythromycin, rifampicin, gemfibrozil & other fibrates.*

ADR: Rash, muscle toxicity, headache, non-cardiac chest pain, nausea, vomiting, diarrhoea, fatigue.

D/INT: Take 1 hour before or 4 hour after cholestyramine or colestipol. *Immunosuppressive drugs, nicotinic acid, erythromycin, rifampicin, gemfibrozil & other fibrates.*

ADR: Rash, muscle toxicity, headache, non-cardiac chest pain, nausea, vomiting, diarrhoea, fatigue.

D/INT: Take 1 hour before or 4 hour after cholestyramine or colestipol. *Immunosuppressive drugs, nicotinic acid, erythromycin, rifampicin, gemfibrozil & other fibrates.*

ADR: Rash, muscle toxicity, headache, non-cardiac chest pain, nausea, vomiting, diarrhoea, fatigue.

D/INT: Take 1 hour before or 4 hour after cholestyramine or colestipol. *Immunosuppressive drugs, nicotinic acid, erythromycin, rifampicin, gemfibrozil & other fibrates.*

ADR: Rash, muscle toxicity, headache, non-cardiac chest pain, nausea, vomiting, diarrhoea, fatigue.

D/INT: Take 1 hour before or 4 hour after cholestyramine or colestipol. *Immunosuppressive drugs, nicotinic acid, erythromycin, rifampicin, gemfibrozil & other fibrates.*

Status & cholest (mmol)	
Desirable <5.2	
Borderline 5.2-6.4	
Abnormal 6.5-7.8	
High >7.8	
Desira <2.3	
Borde 2.3-4.1	
If tota	
High 2.3-4	
Plus hyper	
Very > 4.1	
POI	